Company: DMAAR
Filing Date: 2025-03-31
Form Type: 10-K
Source: 0001213900-25-026240
Chunk: 1192

Company: Drugs Made In America Acquisition Corp.
Filing Date: 2025-03-31
Form: 10-K
Item: Item 16
Chunk 1192
---
.
Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free
of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit
of its internal control over financial reporting. As part of our audit, we are required to obtain an understanding of internal control
over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company's internal control over
financial reporting. Accordingly, we express no such opinion.

Our audit included performing procedures to assess the risks of material
misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures
included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audit also included
evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation
of the financial statements. We believe that our audit provides a reasonable basis for our opinion.

/s/ MaloneBailey, LLP

www.malonebailey.com

We have served as the Company's auditor since 2024.

Houston, Texas

March 31, 2025

F-2

DRUGS MADE IN AMERICA ACQUISITION CORP.

BALANCE SHEET

DECEMBER 31, 2024

    ASSETS 

    Current assets 

    Cash 
    $1,351 
  
    Prepaid expenses and other current assets 
     3,640 
  
    Total Current Assets 
     4,991 
  
    Deferred offering costs 
     545,833 
  
    Total Assets 
    $550,824 

    LIABILITIES AND SHAREHOLDERS’ DEFICIT 

    Current liabilities: 

    Accrued expenses 
    $77,280 
  
    Accrued offering costs 
     56,065 
  
    Promissory note - related party 
     662,324 
  
    Total Liabilities 
     795,669 

    Commitments and contingencies 

    Shareholders’ Deficit: 

    Preference shares, $0.0001 par value; 1,000,000 shares authorized; none issued and outstanding 
     — 
  
    Ordinary shares, $0.0001 par value; 220,000,000 shares authorized; 9,857,143 shares issued and outstanding